Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265485 | 1.00 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL12611747 | 0.83 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL16577961 | 0.83 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL2310526 | 0.82 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL5608012 | 0.81 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL5608007 | 0.81 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL8237191 | 0.81 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL12611746 | 0.81 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL14233567 | 0.80 | SLC7A5 (0.69) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL4624973 | 0.80 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011527670-A | — | — | 2011-11-04 | — | — | JP | claimed |
| EP-2315604-A2 | DICARBA-ANALGUES OF OCTREOTIDE | Advanced Accelerator Applications S.A. (FR) | 2011-05-04 | — | — | EP | claimed |
| WO-2010065572-A1 | SSTR1-SELECTIVE ANALOGS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2010-06-10 | — | — | WO | claimed |
| WO-2010004512-A2 | DICABBA-ANALOGUES OF OCTREOTIDE | ADVANCED ACCELERATOR APPLICATIONS S.A. (FR) | 2010-01-14 | — | — | WO | claimed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11541134-B1 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-20110136741-A1 | DICARBA-ANALOGUES OF OCTREOTIDE | ADVANCED ACCELERATOR APPLICATIONS S.A. (FR) | 2011-06-09 | — | — | US | disclosed |
| EP-2315604-A2 | DICARBA-ANALGUES OF OCTREOTIDE | Advanced Accelerator Applications S.A. (FR) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010065572-A1 | SSTR1-SELECTIVE ANALOGS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010004512-A2 | DICABBA-ANALOGUES OF OCTREOTIDE | ADVANCED ACCELERATOR APPLICATIONS S.A. (FR) | 2010-01-14 | — | — | WO | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541134-B1 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | SLC7A5 190/4885PTGS1 4873/4885ALPI 2325/4885 |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | SLC7A5 3081/4885PTGS1 3021/4885ALPI 2153/4885 |
| US-20110136741-A1 | DICARBA-ANALOGUES OF OCTREOTIDE | SSTR4, SSTR3, SSTR2 | SLC7A5 441/4885PTGS1 4609/4885ALPI 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.